NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

Excellent post, in the passage of time some key and positive factors are forgot or overlooked.

NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK

Cred54675419C's avatar
c red @Cred54675419C
1h
Replying to @TodosInvestor @FlemmingBruce @WayneLee1983
The UK government has set a goal of making the UK a world leading innovator in medicines.

FlemmingBruce's avatar
???? The Danish Dude ???? (Madam/Your highness)
@FlemmingBruce
Replying to @Cred54675419C @TodosInvestor @WayneLee1983
Great info @Cred54675419C ??

The NIHR maintains a “portfolio” of clinical trials that have
been “adopted” as high priorities for the UK. In order to be
selected for the NIHR Portfolio, a proposed clinical trial must go
through multiple layers of review and evaluation. The
evaluation includes the potential significance of the new medical
technology being tested, the quality of the trial design, the
feasibility of the trial, and numerous other factors.


Trials that are selected (“adopted”) for inclusion in the NIHR Portfolio are monitored closely by
the NIHR and the trial sites receive several types of financial and operational support. For
example, the NIHR provides resources and funding for additional staff (e.g., nurses) at the trial
sites to help accelerate the trial. The NIHR also oversees the performance of the sites, and
imposes penalties on the sites for shortfalls such as lags in enrollment.

“We understand that it is relatively rare for a small biotech company to have its clinical trial
‘adopted’ into the NIHR portfolio, especially a Phase III trial,” noted Linda Powers, CEO of NW
Bio. “This important validation of our trial is an exciting development, and the extra resources
and support from the NIHR to the trial sites will be very helpful in accelerating our trial.
https://nwbio.com/nw-bios-phase-iii-trial-with-dcvax-l-for-brain-cancer-adopted-as-a-national-priority-trial-in-uk-2/